In this study, we showed that myeloid-specific RBP-J deficiency attenuated experimental steatohepatitis in mice, and the infusion of exosomes loaded with RBP-J decoy ODNs could represent a promising therapeutic strategy for the treatment of NAFLD. This evidence concerns the gene RBPJ and metabolic dysfunction-associated steatotic liver disease.